BFRIW (NASDAQ) is a cross-listing of BFRI (NASDAQ). Showing primary listing data.
BFRI
Biofrontera Inc.
1W: -0.7%
1M: +0.4%
3M: +19.9%
YTD: +19.1%
1Y: -13.6%
3Y: -93.1%
$0.87
+0.01 (+1.68%)
After Hours: $0.81 (-0.06, -6.32%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$10.1M
52W Range0.536-1.19
Volume165,152
Avg Volume479,154
Beta0.63
Dividend—
Analyst Ratings
Company Info
CEOHermann Luebbert
Employees92
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2021-10-29
Websitebiofrontera.us.com
120 Presidential Way
Woburn, MA 01801
US
Woburn, MA 01801
US
781 245 1325
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Luebbert Hermann | M-Exempt | 137,500 | — | 2026-03-05 |
| Luebbert Hermann | M-Exempt | 137,500 | — | 2026-03-05 |
| Leffler Eugene Frede | M-Exempt | 87,500 | — | 2026-03-05 |
| Leffler Eugene Frede | M-Exempt | 87,500 | — | 2026-03-05 |
| Weber Kevin Daniel | A-Award | 20,000 | $0.90 | 2026-03-04 |